Pfizer Inc. and Astellas Pharma Inc. announced the phase III PROSPER trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy versus ADT alone in patients with non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival.
A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.
